Identification of a potential biomarker for FABP4 inhibition

The power of lipidomics in preclinical drug testing

Karsten Suhre, Werner Römisch-Margl, Martin Hrabé De Angelis, Jerzy Adamski, Gerd Luippold, Robert Augustin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The fatty acid binding protein 4 (FABP4) belongs to the family of lipid chaperones that control intracellular fluxes and compartmentalization of their respective ligands (e.g., fatty acids). FABP4, which is almost exclusively expressed in adipocytes and macrophages, contributes to the development of insulin resistance and atherosclerosis in mice. Lack of FABP4 protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Furthermore, total or macrophage-specific FABP4 deficiency is protective against atherosclerosis in apolipoprotein E-deficient mice. The FABP4 small-molecule inhibitor BMS309403 has demonstrated efficacy in mouse models for type 2 diabetes mellitus and atherosclerosis, resembling phenotypes of mice with FABP4 deficiency. However, despite the therapeutically attractive long-term effects of FABP4 inhibition, an acute biomarker for drug action is lacking. The authors applied mass spectrometry lipidomics analysis to in vitro and in vivo (plasma and adipose tissue) samples upon inhibitor treatment. They report the identification of a potential biomarker for acute in vivo FABP4 inhibition that is applicable for further investigations and can be implemented in simple and fast-flow injection mass spectrometry assays. In addition, this approach can be considered a proof-of-principle study that can be applied to other lipid-pathway targeting mechanisms.

Original languageEnglish
Pages (from-to)467-475
Number of pages9
JournalJournal of Biomolecular Screening
Volume16
Issue number5
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Fatty Acid-Binding Proteins
Biomarkers
Testing
Pharmaceutical Preparations
Protein Deficiency
Atherosclerosis
Macrophages
Mass spectrometry
Insulin Resistance
Mass Spectrometry
Insulin
Lipids
Apolipoproteins E
Nutrition
Medical problems
Adipocytes
Type 2 Diabetes Mellitus
Adipose Tissue
Assays
Fatty Acids

Keywords

  • atherosclerosis
  • biomarkers
  • drug action
  • fatty acid binding protein
  • mass spectroscopy
  • metabolomics
  • type 2 diabetes

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Molecular Medicine
  • Biotechnology

Cite this

Identification of a potential biomarker for FABP4 inhibition : The power of lipidomics in preclinical drug testing. / Suhre, Karsten; Römisch-Margl, Werner; De Angelis, Martin Hrabé; Adamski, Jerzy; Luippold, Gerd; Augustin, Robert.

In: Journal of Biomolecular Screening, Vol. 16, No. 5, 06.2011, p. 467-475.

Research output: Contribution to journalArticle

Suhre, Karsten ; Römisch-Margl, Werner ; De Angelis, Martin Hrabé ; Adamski, Jerzy ; Luippold, Gerd ; Augustin, Robert. / Identification of a potential biomarker for FABP4 inhibition : The power of lipidomics in preclinical drug testing. In: Journal of Biomolecular Screening. 2011 ; Vol. 16, No. 5. pp. 467-475.
@article{789a8fd7e56b43db8a96f8eb03eb6361,
title = "Identification of a potential biomarker for FABP4 inhibition: The power of lipidomics in preclinical drug testing",
abstract = "The fatty acid binding protein 4 (FABP4) belongs to the family of lipid chaperones that control intracellular fluxes and compartmentalization of their respective ligands (e.g., fatty acids). FABP4, which is almost exclusively expressed in adipocytes and macrophages, contributes to the development of insulin resistance and atherosclerosis in mice. Lack of FABP4 protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Furthermore, total or macrophage-specific FABP4 deficiency is protective against atherosclerosis in apolipoprotein E-deficient mice. The FABP4 small-molecule inhibitor BMS309403 has demonstrated efficacy in mouse models for type 2 diabetes mellitus and atherosclerosis, resembling phenotypes of mice with FABP4 deficiency. However, despite the therapeutically attractive long-term effects of FABP4 inhibition, an acute biomarker for drug action is lacking. The authors applied mass spectrometry lipidomics analysis to in vitro and in vivo (plasma and adipose tissue) samples upon inhibitor treatment. They report the identification of a potential biomarker for acute in vivo FABP4 inhibition that is applicable for further investigations and can be implemented in simple and fast-flow injection mass spectrometry assays. In addition, this approach can be considered a proof-of-principle study that can be applied to other lipid-pathway targeting mechanisms.",
keywords = "atherosclerosis, biomarkers, drug action, fatty acid binding protein, mass spectroscopy, metabolomics, type 2 diabetes",
author = "Karsten Suhre and Werner R{\"o}misch-Margl and {De Angelis}, {Martin Hrab{\'e}} and Jerzy Adamski and Gerd Luippold and Robert Augustin",
year = "2011",
month = "6",
doi = "10.1177/1087057111402200",
language = "English",
volume = "16",
pages = "467--475",
journal = "Journal of Biomolecular Screening",
issn = "1087-0571",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Identification of a potential biomarker for FABP4 inhibition

T2 - The power of lipidomics in preclinical drug testing

AU - Suhre, Karsten

AU - Römisch-Margl, Werner

AU - De Angelis, Martin Hrabé

AU - Adamski, Jerzy

AU - Luippold, Gerd

AU - Augustin, Robert

PY - 2011/6

Y1 - 2011/6

N2 - The fatty acid binding protein 4 (FABP4) belongs to the family of lipid chaperones that control intracellular fluxes and compartmentalization of their respective ligands (e.g., fatty acids). FABP4, which is almost exclusively expressed in adipocytes and macrophages, contributes to the development of insulin resistance and atherosclerosis in mice. Lack of FABP4 protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Furthermore, total or macrophage-specific FABP4 deficiency is protective against atherosclerosis in apolipoprotein E-deficient mice. The FABP4 small-molecule inhibitor BMS309403 has demonstrated efficacy in mouse models for type 2 diabetes mellitus and atherosclerosis, resembling phenotypes of mice with FABP4 deficiency. However, despite the therapeutically attractive long-term effects of FABP4 inhibition, an acute biomarker for drug action is lacking. The authors applied mass spectrometry lipidomics analysis to in vitro and in vivo (plasma and adipose tissue) samples upon inhibitor treatment. They report the identification of a potential biomarker for acute in vivo FABP4 inhibition that is applicable for further investigations and can be implemented in simple and fast-flow injection mass spectrometry assays. In addition, this approach can be considered a proof-of-principle study that can be applied to other lipid-pathway targeting mechanisms.

AB - The fatty acid binding protein 4 (FABP4) belongs to the family of lipid chaperones that control intracellular fluxes and compartmentalization of their respective ligands (e.g., fatty acids). FABP4, which is almost exclusively expressed in adipocytes and macrophages, contributes to the development of insulin resistance and atherosclerosis in mice. Lack of FABP4 protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Furthermore, total or macrophage-specific FABP4 deficiency is protective against atherosclerosis in apolipoprotein E-deficient mice. The FABP4 small-molecule inhibitor BMS309403 has demonstrated efficacy in mouse models for type 2 diabetes mellitus and atherosclerosis, resembling phenotypes of mice with FABP4 deficiency. However, despite the therapeutically attractive long-term effects of FABP4 inhibition, an acute biomarker for drug action is lacking. The authors applied mass spectrometry lipidomics analysis to in vitro and in vivo (plasma and adipose tissue) samples upon inhibitor treatment. They report the identification of a potential biomarker for acute in vivo FABP4 inhibition that is applicable for further investigations and can be implemented in simple and fast-flow injection mass spectrometry assays. In addition, this approach can be considered a proof-of-principle study that can be applied to other lipid-pathway targeting mechanisms.

KW - atherosclerosis

KW - biomarkers

KW - drug action

KW - fatty acid binding protein

KW - mass spectroscopy

KW - metabolomics

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79959400390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959400390&partnerID=8YFLogxK

U2 - 10.1177/1087057111402200

DO - 10.1177/1087057111402200

M3 - Article

VL - 16

SP - 467

EP - 475

JO - Journal of Biomolecular Screening

JF - Journal of Biomolecular Screening

SN - 1087-0571

IS - 5

ER -